N4 101 / Thalia Therapeutics - LARVOL DELTA

N4 101 In Vivo Study Results (Financial Times) - "N4 Pharma plc...is pleased to announce positive results from its first in vivo study evaluating the use of its Nuvec proof-of-concept programme, N4 101, an orally delivered anti-inflammatory treatment for Inflammatory Bowel Disease (IBD)....Reduction in inflammation: both single and dual-loaded Nuvec particles demonstrated marked improvements compared with controls across all key indicators of colitis, including Disease Activity Index (DAI), colon length, and body weight loss....Sustained therapeutic effect: six days after the final administration, both single and dual-loaded targeted Nuvec particles showed a near complete reduction in TNF alpha levels in intestinal tissues."

Preclinical • Inflammatory Bowel Disease